3-methoxy-2,2,5,5-tetramethylhexane | 79802-57-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-methoxy-2,2,5,5-tetramethylhexane
• CAS: 79802-57-6
• 化学式: C₁₁H₂₄O
• 分子量: 172.311
• InChiKey: HXEOESMYAARHLX-UHFFFAOYSA-N

物化性质

• 沸点：
  168.8±8.0 °C(Predicted)
• 密度：
  0.794±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (E)-2,2,5,5-tetramethylhex-3-ene 在 甲基锂 、 diborane(6) 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 44.0h， 生成 3-methoxy-2,2,5,5-tetramethylhexane
  参考文献：
  名称：

  Photochemistry of alkenes. 8. Sterically congested alkenes

  摘要：

  DOI：

  10.1021/ja00414a042

文献信息

• Bioadhesive Polymers
  申请人：Jacob Jules

  公开号：US20110086095A1

  公开（公告）日：2011-04-14

  Polymers and compositions, collectively “bioadhesive materials”, with improved bioadhesive properties have been developed. One or more compounds comprising: a) an aromatic moiety comprising two or more hydroxyl substituents, methoxy substituents, substituents hydrolyzable to hydroxyl substituents, or a combination thereof, and b) a primary or secondary amino moiety are either covalently attached to a polymer or are physically mixed with a polymer to form a bioadhesive material. These bioadhesive materials can be used, for example, to fabricate new drug delivery or diagnostic systems with increased residence time at tissue surfaces, and consequently increase the bioavailability of a drug or a diagnostic agent.

  已经开发出具有改进生物粘附性能的聚合物和组合物，统称为“生物粘附材料”。其中一个或多个化合物包括：a）含有两个或更多羟基取代基，甲氧基取代基，水解成羟基取代基或其组合的芳香基团，和b）一种一级或二级氨基团，或者将它们共价地附着在聚合物上，或者将它们物理混合在一起形成生物粘附材料。这些生物粘附材料可以用于制造新的药物输送或诊断系统，增加在组织表面的停留时间，从而增加药物或诊断剂的生物利用度。
• BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US20150273068A1

  公开（公告）日：2015-10-01

  The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

  本发明涉及一种阳离子脂质，其在脂质部分（例如，疏水链）中具有一个或多个可生物降解的基团。这些阳离子脂质可以被纳入到脂质颗粒中，用于传递活性物质，例如核酸。本发明还涉及包括中性脂质、可减少聚集的脂质、本发明中的阳离子脂质和可选地，甾醇的脂质颗粒。该脂质颗粒还可以包括治疗剂，例如核酸。
• PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS
  申请人：Nangia Avinash

  公开号：US20100316712A1

  公开（公告）日：2010-12-16

  The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. The invention relates to drug compositions and dosage forms comprising said drug composition; methods of manufacturing the drug compositions and dosage forms; and methods of treatment, comprising administering the drug composition and dosage form to an individual. In certain embodiments, the drug compositions and dosage forms comprise carbidopa and levodopa in a formulation suitable for once-daily administration.

  该发明涉及改进某些神经障碍/疾病的治疗，例如帕金森病和其他运动障碍。该发明涉及包含该药物组合的药物配方和剂型；制造药物配方和剂型的方法；以及治疗方法，包括向个体注射该药物组合和剂型。在某些实施例中，药物配方和剂型包括卡比多巴和左旋多巴，适合一次日常用量。
• KROPP, P. J.;TISE, F. P., J. AMER. CHEM. SOC., 1981, 103, N 24, 7293-7298
  作者：KROPP, P. J.、TISE, F. P.

  DOI：——

  日期：——
• IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US20150306039A1

  公开（公告）日：2015-10-29

  The present invention relates to lipid nanoparticles containing a biodegradable cationic lipid which provide improved delivery of active pharmaceutical ingredients, such as siRNA.